SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant     [X]
Filed by a Party other than the Registrant     [   ]

Check the appropriate box:

[   ]     Preliminary Proxy Statement
[   ]     Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
[X]     Definitive Proxy Statement
[   ]     Definitive Additional Materials
[   ]     Soliciting underss.240.14a-12

VASCULAR SOLUTIONS, INC.
(Name of Registrant as Specified in its Charter)

_______________________________________________________________
(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]     No fee required.
[   ]     Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:______________________

(2) Aggregate number of securities to which transaction applies: _____________________

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):________________

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

[   ]      Fee paid previously with preliminary materials.

[   ]      Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid: ________________________

(2) Form, Schedule or Registration Statement No.: ________________________

(3) Filing Party: ________________________

(4) Date Filed: ________________________

Dear Fellow Shareholder:

        You are cordially invited to attend the 2004 annual meeting of shareholders of Vascular Solutions, Inc., which will be held at the Radisson Hotel & Conference Center, 3131 Campus Drive, Plymouth, Minnesota beginning at 3:30 p.m. on Thursday, April 22, 2004.

        This booklet contains your official notice of the 2004 annual meeting of shareholders and a proxy statement that includes information about matters to be acted upon at the annual meeting. Officers and Directors of Vascular Solutions, Inc. will be on hand to review the company’s operations and to answer questions and discuss matters that may properly arise.

        Whether or not you plan to attend the annual meeting, please complete, sign, date and mail the enclosed proxy card promptly. If you attend the annual meeting, you may revoke your proxy and vote in person if you wish, even if you have previously returned your proxy card.

        I sincerely hope that you will be able to attend our annual meeting to review the past year and our future plans.

Sincerely,

Howard C. Root
Chief Executive Officer

VASCULAR SOLUTIONS, INC.
6464 Sycamore Court
Minneapolis, Minnesota 55369

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD APRIL 22, 2004

        The 2004 annual meeting of the shareholders of Vascular Solutions, Inc., a Minnesota corporation, will be held at the Radisson Hotel & Conference Center, 3131 Campus Drive, Plymouth, Minnesota, beginning at 3:30 p.m. on Thursday, April 22, 2004 for the following purposes:

1. To elect seven directors to serve on the Board of Directors for a term of one year and until their successors are duly elected and qualified.

2. To ratify the appointment of Ernst & Young LLP as Vascular Solutions, Inc.‘s independent auditor for 2004.

3. To transact such other business as may properly come before the meeting or any adjournment thereof.

        The Board of Directors recommends that an affirmative vote be cast in favor of all nominees and for ratification of the independent auditor.

        Only holders of record of common stock at the close of business on March 10, 2004 will be entitled to notice of and to vote at the annual meeting or any adjournment thereof.

        It is important that your shares of common stock be represented at the annual meeting. You are urged to complete, sign and date the accompanying proxy card, which is solicited by the Board of Directors of Vascular Solutions, and mail it promptly in the enclosed envelope. Your proxy will not be used if you attend and vote at the annual meeting in person.

By order of the Board of Directors



Michael Nagel
Secretary

March 24, 2004

IMPORTANT: PLEASE RETURN EACH PROXY CARD SENT TO YOU.

PROXY STATEMENT

        This proxy statement is provided in connection with the 2004 annual meeting of shareholders of Vascular Solutions, Inc. and any adjournment or postponement of the meeting. The accompanying proxy is solicited by the Board of Directors of Vascular Solutions. This proxy statement is dated March 24, 2004. This proxy statement, the accompanying form of proxy and Vascular Solutions’ annual report are first being sent or given to shareholders beginning on or about March 24, 2004.

Record Date; Shareholders Entitled to Vote; Quorum

        Holders of record of the shares of Vascular Solutions common stock at the close of business on March 10, 2004, will be entitled to vote on all matters at the annual meeting. Each share of common stock will be entitled to one vote. On March 10, 2004, a total of 13,915,500 shares of common stock were outstanding. A majority of the voting power of the outstanding shares of common stock entitled to vote, represented in person or by proxy, will be required to constitute a quorum for the annual meeting.

Voting Your Shares

        The Vascular Solutions Board of Directors is soliciting proxies from the Vascular Solutions shareholders. By completing and returning the accompanying proxy, you will be authorizing Howard Root and Michael Nagel to vote your shares. If your proxy is properly signed and dated it will be voted as you direct. If you attend the annual meeting in person, you may vote your shares by completing a ballot at the meeting.

Changing Your Vote by Revoking Your Proxy

        Your proxy may be revoked at any time before it is voted at the annual meeting by giving notice of revocation to Vascular Solutions, in writing, by execution of a later dated proxy or by attending and voting at the annual meeting.

How Proxies Are Counted

        If you return a signed and dated proxy card but do not indicate how the shares are to be voted, those shares will be voted FOR each of the nominees and the listed proposals. Votes cast by proxy or in person at the annual meeting will be tabulated by the election inspectors appointed for the annual meeting.

        Shares voted as abstentions on any matter (or a “withhold vote for” as to directors) will be counted for purposes of determining the presence of a quorum at the annual meeting and treated as unvoted, although present and entitled to vote, for purposes of determining the approval of each matter as to which a shareholder has abstained. If a broker submits a proxy that indicates the broker does not have discretionary authority as to certain shares to vote on one or more matters, those shares will be counted for purposes of determining the presence of a quorum at the meeting, but will not be considered as present and entitled to vote with respect to such matters.

-2-

        The Board of Directors knows of no other matters to be presented for action at the annual meeting other than those set forth herein. If any other matters properly come before the annual meeting, however, the persons named in the proxy will vote on such other matters and/or for other nominees in accordance with their best judgment. This includes a motion to adjourn or postpone the annual meeting to solicit additional proxies.

Cost of Solicitation

        All expenses in connection with this solicitation will be paid by Vascular Solutions. Officers, Directors and regular employees of Vascular Solutions, who will receive no extra compensation for their services, may solicit proxies by telephone or electronic transmission.

PROPOSAL 1:
ELECTION OF DIRECTORS

        Seven Directors have been nominated for election to our Board of Directors at the 2004 annual meeting of shareholders to hold office for a term of one year and until their successors are duly elected and qualified (except in the case of earlier death, resignation or removal). In the unlikely event that the nominees are not candidates for election at the annual meeting, the persons named as proxies will vote for such other persons as the Board of Directors or proxies may designate.

        Information regarding the nominees to the Board of Directors is set forth below.

        Gary Dorfman, M.D., age 52, joined our Board of Directors in October 2002. Dr. Dorfman is the President of General Vascular Services, LTD, a medical practice consulting firm, and is Professor Emeritus of Diagnostic Radiology at Brown University School of Medicine. Previously, Dr. Dorfman was Medical Director, Office of Clinical Management at Rhode Island Hospital. Dr. Dorfman is a Fellow of the American College of Radiology and a past President of the Society of Cardiovascular and Interventional Radiology.

        John Erb, age 55, joined our Board of Directors in October 2002. Mr. Erb has over 25 years experience in the medical device industry. Since 2001, Mr. Erb has served as the Chief Executive Officer of CHF Solutions, a medical device company involved in the treatment of congestive heart failure. From 1997 through 2001, Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral stents. IntraTherapeutics was acquired by Sulzer Medica for $145 million in 2001. Previously, Mr. Erb was Vice President of Worldwide Operations for Schneider Worldwide, a division of Pfizer, Inc. Mr. Erb serves as a director of CryoCath Technologies, as well as several private companies.

        James Jacoby, Jr., age 41, has served on our Board of Directors since February 1999. Mr. Jacoby has been a Managing Director of the Health Care and Life Sciences Group of the Corporate Finance Department of Stephens Inc., an Arkansas-based investment banking firm, since December 1999 and previously was Vice President, Corporate Finance Department of Stephens Inc. since 1994.

-3-

From 1990 through 1994, Mr. Jacoby was Vice President, Mergers and Acquisitions Department of Chemical Banking Corporation in New York and London.

        Michael Kopp, age 47, has served on our Board of Directors since November 2000. Mr. Kopp has over twenty years experience in the medical device industry. He has been a private investor and industry consultant since September 1999. From April 1995 to August 1999 Mr. Kopp was President and CEO of IsoStent, Inc., a medical device company which was acquired by Johnson and Johnson. From January 1994 to March 1995 Mr. Kopp was President and CEO of Devices for Vascular Intervention, Inc., a medical device company which was acquired by Eli Lilly and Company. He has served as a director of Prolifix, Inc., a medical device company, since October 1996 and also has served as a director of Spiration, Inc., a medical device company, since October 1999.

        Richard Nigon, age 56, has been a member of our Board of Directors since November 2000. Mr. Nigon has been Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard since February 2001. From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of Dantis, Inc., a web hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young since 1970, serving as a partner since 1981. While at Ernst & Young, Mr. Nigon served as the Director of Ernst & Young’s Twin Cities Entrepreneurial Services Group and was the coordinating partner on several publicly-traded companies in the consumer retailing and manufacturing industries. Mr. Nigon serves as a director of Compex Technologies, Inc., a medical device company, and Endocardial Solutions, Inc., a medical device company.

        Paul O’Connell, age 51, joined our Board of Directors in January 2002. Mr. O’Connell has been Vice President of the Vascular Interventional Products Group of B. Braun Medical, an international medical device company, since July 2001. From 1999 through 2001, Mr. O’Connell provided marketing and technical support consulting services to medical device companies. Mr. O’Connell was the owner of Sablier, a medical device company, from 1998 through 1999 where he developed new technologies for the treatment of thromboembolic diseases and for distal protection during carotid endartorectomy. From 1993 through 1998, Mr. O’Connell was Vice-President and General Manager of the Vena Tech division of B. Braun Medical, a medical device business he originally co-founded in 1988 and sold to B. Braun Medical in 1993.

        Howard Root, age 43, has served as our Chief Executive Officer and a director since he co-founded Vascular Solutions in February 1997. From 1990 to 1995, Mr. Root was employed by ATS Medical, Inc., a mechanical heart valve company, most recently as Vice President and General Counsel. Prior to joining ATS Medical, Mr. Root practiced corporate law, specializing in representing emerging growth companies, at the law firm of Dorsey & Whitney LLP for over five years.

        The Board has determined that all of the members of the Board continuing in office after this Annual Meeting are “independent directors” within the meaning of Rule 4200 of the National Association of Securities Dealers, Inc. (“NASD”), other than Mr. Howard Root, who is not considered independent because he is an executive officer of the Company.

-4-

        OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF THE NOMINEES.

        The affirmative vote of a majority of the shares of Vascular Solutions common stock present and entitled to vote at the 2004 annual meeting of shareholders is necessary to elect each nominee. Proxies will be voted in favor of the nominees unless otherwise specified.

Meetings Attendance

        Each of our directors is expected to make a reasonable effort to attend all meetings of the Board, applicable committee meetings and our annual meeting of shareowners. All of our directors attended our 2003 annual meeting. During 2003, the Board of Directors held five meetings. Each director holding office during the year attended at least 75% of the total number of meetings of the Board of Directors (held during the period for which they were a Director) and committees of the board on which they served.

Committees of the Board of Directors

        The Board of Directors has an Audit Committee and a Compensation Committee, which are described below. The Board of Directors does not have a Nominating Committee. The Board believes that the entire Board of Directors should be involved with nominating directors.

        The Board of Directors has an Audit Committee composed of Mr. Jacoby, Mr. Erb and Mr. Nigon, all of whom are “independent” under the current NASDAQ stock market listing standards. The Board has identified Mr. Jacoby, Mr. Erb and Mr. Nigon who meet the definition of an “Audit Committee Financial Expert” recently established by the Securities and Exchange Commission. The Audit Committee’s responsibilities include facilitating our relationship with independent auditors; reviewing and assessing the performance of our accounting and finance personnel; communicating to our Board of Directors the results of work performed by and issues raised by our independent auditors and legal counsel; and evaluating our management of assets and reviewing policies relating to asset management. The Audit Committee held four meetings during 2003.

        The Board of Directors has a Compensation Committee composed of Mr. Kopp, Mr. Jacoby and, Mr. O’Connell. The Compensation Committee’s responsibilities include establishing salaries, incentives, and other forms of compensation for our directors and officers; administering our incentive compensation and benefits plans; and recommending policies relating to such incentive compensation and benefits plans. The Compensation Committee held one formal meeting during 2003.

        The Board of Directors is responsible for determining the slate of director nominees for election by shareowners. All director nominees approved by the Board and all individuals appointed to fill vacancies created between our annual meetings of shareowners are required to stand for election by our shareowners at the next annual meeting.

-5-

        The Board of Directors determines the required selection criteria and qualifications of director nominees based upon the needs of the Company at the time nominees are considered. A candidate must possess the ability to apply good business judgment and must be in a position to properly exercise his or her duties of loyalty and care. Candidates should also exhibit proven leadership capabilities, high integrity and experience with a high level of responsibilities within their chosen fields, and have the ability to quickly grasp complex principles of business, finance, international transactions and medical technologies. In general, candidates will be preferred who hold an established executive level position in the medical field, finance, law, education, research or government. The Board of Directors will consider these criteria for nominees identified by the Board, by shareowners, or through some other source. When current Board members are considered for nomination for reelection, the Board also takes into consideration their prior Vascular Solutions Board contributions, performance and meeting attendance records.

        The Board of Directors will consider qualified candidates for possible nomination that are submitted by our shareowners. Shareowners wishing to make such a submission may do so by sending the following information to the Board of Directors c/o Corporate Secretary, Vascular Solutions, Inc., 6464 Sycamore Court, Minneapolis, MN 55369: (1) name of the candidate and a brief biographical sketch and resume; (2) contact information for the candidate and a document evidencing the candidate’s willingness to serve as a director if elected; and (3) a signed statement as to the submitting shareowner’s current status as a shareowner and the number of shares currently held.

        The Board of Directors conducts a process of making an assessment of each proposed nominee based upon the resume and biographical information, an indication of the individual’s willingness to serve and other information. On the basis of information learned during this process, the Board of Directors determines which nominee(s) to submit for election at the next annual meeting. The Board uses the same process for evaluating all nominees, regardless of the original source of the nomination. The Board of Directors will include the process of nominating directors as a Board resolution at the next scheduled Board of Director’s meeting.

        Historically, the Company has not adopted a formal process for shareholder communications with the Board. Nevertheless, every effort has been made to ensure that the views of shareholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to shareholders in a timely manner. Shareholders who wish to communicate with the Board of Directors may do so by writing to: Vascular Solutions, Inc., Board of Directors, 6464 Sycamore Court, Minneapolis, MN 55369.

        No candidates for director nominations were submitted to the Board of Directors by any shareowner in connection with the 2004 annual meeting. Any shareowners desiring to present a nomination for consideration by the Board o f Directors prior to our 2005 annual meeting must do so prior to November 24, 2004 in order to provide adequate time to duly consider the nominee and comply with our bylaws.

-6-

Director Compensation

        During 2003, we paid our non-employee directors $1,500 for each meeting attended in person, and $500 for each meeting attended by telephone. In addition, we paid our non-employee committee members an additional $500 for each meeting attended in person or by telephone. We also reimbursed directors for out-of-pocket expenses incurred in attending board meetings. Each non-employee director also receives an option to purchase 10,000 shares of our common stock on the date of his or her election to our Board of Directors and the date of each re-election thereafter with an exercise price equal to fair market value on such date.

REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

        The Audit Committee of our Board of Directors is composed of the following non-employee directors: Mr. Jacoby, Mr. Erb, and Mr. Nigon. Mr. Nigon currently serves as the Chairman of the Audit Committee. All of the members of the Audit Committee are independent for purposes of the Nasdaq listing requirements. The Audit Committee operates under a written charter adopted by the Board of Directors, a copy of which is attached to this Proxy Statement as Exhibit A. The Audit Committee recommends to the Board of Directors, and submits for shareholder ratification, the appointment of our independent auditor Ernst & Young LLP.

        Management is responsible for Vascular Solutions’ internal controls and the financial reporting process. Our independent auditor is responsible for performing an independent audit of our consolidated financial statements in accordance with generally accepted auditing standards and to issue a report on our financial statements. The Audit Committee’s responsibility is to monitor and oversee these processes.

        In this context, the Audit Committee has met and held discussions with management and the independent auditor. Management represented to the Audit Committee that Vascular Solutions’ consolidated financial statements were prepared in accordance with generally accepted accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with management and the independent auditor. The Audit Committee discussed with the independent auditor matters required to be discussed by Statement on Auditing Standards No. 61 (Communications with Audit Committees).

        Our independent auditor also provided to the Audit Committee the written disclosure required by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), and the Audit Committee discussed with the independent auditor the auditing firm’s independence. The Committee also considered whether non-audit services provided by the independent auditor during the last fiscal year were compatible with maintaining the independent auditor’s independence.

        Based upon the Audit Committee’s discussion with management and the independent auditor and the Audit Committee’s review of the representation of management and the report of the independent auditor to the Audit Committee, the Audit Committee recommended to the Board of

-7-

Directors that the audited consolidated financial statements be included in Vascular Solutions’ Annual report on Form 10-K for the fiscal year ended December 31, 2003 filed with the Securities and Exchange Commission.

Members of the Audit Committee

Richard Nigon, Chairman
John Erb
James Jacoby, Jr.

COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION

        The Compensation Committee of our Board of Directors is composed of the following non-employee directors: Mr. Kopp, Mr. Jacoby and, Mr. O’Connell. Mr. Kopp currently serves as Chairman of the Compensation Committee. The Compensation Committee advises the Chief Executive Officer and the Board of Directors on matters of compensation philosophy and recommends salaries, incentives and other forms of compensation for our officers and other key employees. The Compensation Committee has reviewed and is in accord with the compensation paid to executive officers in 2003.

General Compensation Policy

        We are committed to attracting, hiring and retaining an experienced management team that can successfully manufacture and sell our existing medical devices and develop new products. The fundamental policy of the Compensation Committee is to provide our executive officers with competitive compensation opportunities based upon their contribution to our development and financial success and long-term shareholder interest, as well as the officers’ personal performance. It is the Compensation Committee’s objective to have a portion of each executive officer’s compensation contingent upon overall company performance as well as upon such executive officer’s own level of performance. Accordingly, the compensation package for each executive officer is comprised of three elements: (i) base salary which reflects individual performance and is designed primarily to be competitive with salary levels in the industry; (ii) bonus payments contingent upon specific corporate and individual milestones; and (iii) long-term stock-based incentive awards which strengthen the mutuality of interests between the executive officers and our shareholders.

Base Salary

        The base salary is established as a result of the Compensation Committee’s analysis of each executive officer’s individual performance during the prior year, our overall performance during the prior year and historical compensation levels within the executive officer group. The Compensation Committee believes executive salaries must be sufficient to attract and retain key individuals. Salaries are also based on experience level and are intended to be competitive with salaries paid to comparable executives in similar positions at other medical device companies of comparable size.

-8-

Bonus Awards for 2003

        Bonus awards are provided under a Management Incentive Compensation Plan. At the beginning of each year certain performance objectives, including corporate, department and personal goals, are set. At the end of the year management personnel that are eligible for bonus awards have their performance measured against these goals. Based upon progress toward meeting these goals, bonus awards are paid. In December 2003, the Compensation Committee approved bonuses for executive officers and certain other employees for recognition of accomplished objectives during 2003.

Long-Term Incentive Compensation

        Long-term incentives are provided through the grant of stock options. The grants are designed to align the interest of each executive officer with those of our shareholders and provide each individual with an incentive to manage our business from the perspective of an owner with an equity stake in the business. In general, we view option grants as incentives for future performance and not as compensation for past accomplishments. Executive officers are granted a stock option at the time they commence service and are eligible for annual grants thereafter. In determining the number of shares subject to stock option grants, the Committee takes into consideration the job responsibilities, experience and contributions of the individual as well as the recommendations of the Chief Executive Officer. The options vest over a period of several years and are generally not exercisable for at least one year after the date of grant. Each option grant allows the individual to acquire shares of our Common Stock at a fixed price per share over a ten-year period of time. Executive officers receive gains from stock options only to the extent that the fair market value of the stock has increased since the date of the option grant.

CEO Compensation

        The Compensation Committee’s determination of our Chief Executive Officer’s salary, bonus and stock option grants follows the policies set forth above for all executive compensation. The Committee seeks to establish a level of base salary competitive with that paid by companies within the industry which are of comparable size, and a bonus contingent upon specific corporate objectives. In addition, a significant percentage of the total compensation package is contingent upon Vascular Solutions’ performance and stock price appreciation.

        During 2003, Mr. Root, the Company’s Chief Executive Officer, was paid a base salary of $245,000. In addition, a bonus of $41,895 was paid in January 2004 based upon the accomplishment of specific milestones in 2003. Those milestones included development and launch of four new products for the Company’s future growth and the reduction in the Company’s operating loss. Mr. Root received a stock option grant for 50,000 shares during 2003. These stock option and bonus awards reflected the Compensation Committee’s judgment as to Mr. Root’s individual performance and the overall performance of Vascular Solutions. The Committee also believes that stock options granted to Mr. Root to date provide a significant and appropriate tie between overall compensation and the company’s performance over the long term.

-9-

Compliance with Internal Revenue Code Section 162(m)

        As a result of Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), which was enacted into law in 1993, we will not be allowed a federal income tax deduction for compensation paid to certain executive officers to the extent that compensation exceeds $1 million per officer in any one year. This limitation will apply to all compensation paid to the covered executive officers which is not considered to be performance based. Compensation which does qualify as performance-based compensation will not have to be taken into account for purposes of this limitation. The Committee believes that options granted under the Vascular Solutions Stock Option Plan will meet the requirements for qualifying as performance-based.

        Section 162(m) of the Code did not affect the deductibility of compensation paid to our executive officers in 2001 and is not anticipated to affect the deductibility of such compensation expected to be paid in the foreseeable future. The Committee will continue to monitor this matter and may propose additional changes to the executive compensation program if warranted.

Members of the Compensation Committee

Michael Kopp, Chairman
James Jacoby, Jr.
Paul O’Connell

Employment Agreements

        We have entered into employment agreements with each of our executive officers. The employment agreements provide for employment “at will” which may be terminated by either party for any reason upon ten working days’ prior written notice. The base salary and any discretionary bonus for each of the executive officers is determined by the compensation committee of our Board of Directors. During the term of his or her employment agreement and for a period of one year after its termination, each executive officer is prohibited from competing with us in the vascular sealing device field.

Code of Ethics

        We have adopted a code of ethics that applies to all of our directors, officers (including our chief executive officer, chief financial officer, chief accounting officer, and any person performing similar functions) and employees. We have made our Code of Ethics available by filing it as Exhibit 14 with our 2003 Form 10-K.

-10-

EXECUTIVE COMPENSATION AND OTHER INFORMATION

        The following table sets forth all compensation awarded to, earned by or paid for services rendered to us in all capacities during each of the last three fiscal years by our Chief Executive Officer and the four other most highly compensated executive officers whose salary and bonus earned in 2003 exceeded $100,000.

Summary Compensation Table

	Annual Compensation					Long-Term Compensation
Name and Principal Position	Year	Salary		Bonus		Securities Underlying Options(1)			All Other Compensation(2)
Howard Root	2003	$	245,000	$	41,895		50,000		$	5,827
Chief Executive Officer	2002		210,000		30,000		—			2,984
	2001		200,000		15,000		50,000			2,586
Michael Nagel	2003		215,000		26,513		115,000	(5)		9,389
Vice President of Sales	2002		200,000		25,000		—			8,310
and Marketing and	2001		175,000		10,938		40,000			7,312
Secretary
James Quackenbush	2003		160,000		23,450		65,000	(6)		9,649
Vice President of	2002		150,000		15,000		—			8,498
Manufacturing	2001		135,000		16,875		15,000			7,533
Deborah Neymark	2003		170,000		22,791		45,000	(7)		5,880
Vice President of	2002		150,000		20,000		—			4,694
Regulatory Affairs,	2001		137,500		48,594		32,500			7,509
Quality Systems &
Clinical Research(3)
James Hennen	2003		100,000		13,601		10,000			5,415
Chief Financial Officer(4)

_________________

(1) Represents options granted pursuant to our Stock Option and Stock Award Plan.

(2) Represents premiums we pay for health insurance benefits and matching contributions to our 401(k) plan.

(3) Mrs. Neymark joined us as Vice President of Regulatory Affairs, Quality Systems and Clinical Research in October 2000. Mrs. Neymark's 2001 bonus includes deferred payment of a signing bonus.

(4) Mr. Hennen became an executive officer effective December 31, 2003.

(5) Includes 90,000 options re-granted to Mr. Nagel under the stock option exchange offer.

(6) Includes 50,000 options re-granted to Mr. Quackenbush under the stock option exchange offer.

(7) Includes 25,000 options re-granted to Mrs. Neymark under the stock option exchange offer.

-11-

        The following table sets forth information concerning the exercise of options during 2003 and unexercised options held as of December 31, 2003 by each of the executive officers named in the Summary Compensation Table.

Aggregated Option Exercises in 2003 and Year-End Option Values

			Number of Securities Underlying Unexercised Options at December 31, 2003				Value of Unexercised In-the-Money Options as of December 31, 2003(1)
Name	Shares Acquired On Exercise	Value Realized	Exercisable		Unexercisable		Exercisable		Unexercisable
Howard Root	—	$ —		229,711		86,500	$	116,200	$	290,140
Michael Nagel	—	—		125,800		54,200	$	585,038	$	257,262
James Quackenbush	—	—		42,700		27,300	$	210,272	$	133,478
Deborah Neymark	—	—		23,550		28,950	$	111,693	$	139,857
James Hennen(2)	—	—		3,840		16,160	$	15,427	$	75,393

_________________

(1) “Value” has been determined based on the difference between the last sale price of Vascular Solutions’ common stock as reported by the Nasdaq National Market System on December 31, 2003 ($5.87) and the per share option exercise price, multiplied by the number of shares subject to the in-the-money options.

(2) Mr. Hennen became an executive officer effective December 31, 2003.

-12-

EQUITY COMPENSATION PLAN INFORMATION

        The following table sets forth information about our common stock that may be issued upon exercise of options and rights under all of our equity compensation plans as of December 31, 2003, including the Stock Option and Stock Award Plan, and the Employee Stock Purchase Plan. Our Stockholders have approved all of these plans.

Plan Category	Number of securities to be issued upon exercise of outstanding options and rights	Weighted average Exercise Price of outstanding options and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding outstanding options, and rights)
Equity compensation
plans approved by
stockholders	1,505,171	$2.50	1,504,767(1)(2)
Equity compensation
plans not approved
by stockholders	None	None	None
Total	1,505,171	$2.50	1,504,767

(1)
 Includes 1,043,574 for our stock option plan. The available shares for our stock option plan automatically increases by the lesser of:
          •          500,000 shares;
          •           5% of the common-equivalent shares outstanding at the end of our prior fiscal year; or
          •           a smaller amount determined by our board of directors or the committee administering the Plan.

(2)  Includes 461,193 for our employee stock purchase plan. The available shares for our employee stock purchase plan automatically increases by the lesser of:
          •           200,000 shares;
          •           2% of the common-equivalent shares outstanding at the end of our prior fiscal year; or
          •           a smaller amount determined by our board of directors or the committee administering the Plan.

-13-

        The following table contains information concerning the grant of stock options under our Stock Option and Stock Award Plan during 2003 to each of the executive officers named in the Summary Compensation Table.

Stock Options Granted in 2003

	Individual Grants(1)									Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term(3)
Name	Number of Securities Underlying Options Granted			Percent of Total Options Granted To Employees in Fiscal Year(2)			Exercise Price Per Share		Expiration Date	5%		10%
Howard Root		50,000			5.6	%	$	0.84	Feb. 18, 2013	$	26,414	$	66,937
Michael Nagel		25,000			2.8			0.84	Feb. 18, 2013		13,207		33,469
		25,000	(4)		2.8			0.84	Feb. 18, 2013		13,207		33,469
		20,000	(4)		2.2			0.84	Feb. 18, 2013		10,565		26,775
		20,000	(4)		2.2			0.84	Feb. 18, 2013		10,565		26,775
		15,000	(4)		1.7			0.84	Feb. 18, 2013		7,924		20,081
		10,000	(4)		1.1			0.84	Feb. 18, 2013		5,283		13,387
James Quackenbush		27,500	(4)		3.1			0.84	Feb. 18, 2013		14,527		36,815
		15,000			1.7			0.84	Feb. 18, 2013		7,924		20,081
		10,000	(4)		1.1			0.84	Feb. 18, 2013		5,283		13,387
		10,000	(4)		1.1			0.84	Feb. 18, 2013		5,283		13,387
		2,500	(4)		0.3			0.84	Feb. 18, 2013		1,321		3,347
Deborah Neymark		25,000	(4)		2.8			0.84	Feb. 18, 2013		13,207		33,469
		20,000			2.2			0.84	Feb. 18, 2013		10,565		26,775
James Hennen		10,000			1.1			0.84	Feb. 18, 2013		5,283		13,387

_________________

(1) Each option represents the right to purchase one share of Vascular Solutions common stock. The options shown in this column are granted pursuant to our Stock Option and Stock Award Plan. The options vest in twelve monthly installments beginning three years after the date of grant. The term of each option is ten years.

(2)
In 2003, Vascular Solutions granted employees options to purchase an aggregate of 889,070 shares of common stock.

-14-

(3) The 5% and 10% assumed annual rates of compounded stock price appreciation are mandated by rules of the Securities and Exchange Commission and do not represent Vascular Solutions’ estimate or projection of Vascular Solutions’ future common stock prices. These amounts represent certain assumed rates of appreciation only. Actual gains, if any, on stock option exercises are dependent on the future performance of the common stock and overall stock market conditions. The amounts reflected in the table may not necessarily be achieved.

(4)
Stock option was re-granted under the stock option exchange offer.

-15-

OPTION EXCHANGE OFFER

        On July 16, 2002, the Board of Directors approved an option exchange program pursuant to which certain employees (excluding the Chief Executive Officer and Directors) could voluntarily exchange for cancellation outstanding stock options with an exercise price equal to or above $3.00 per share. The Board of Directors agreed that no earlier than six months and one day after the voluntary cancellation it would grant replacement options to each option holder equal to the number of options voluntarily cancelled, and that the replacement options would have the same vesting schedule as the cancelled options. The option exchange offer expired on August 14, 2002 and the Company accepted for cancellation and exchange options to purchase 467,070 shares of Common Stock held by 77 option holders, representing approximately 83% of the options eligible for cancellation. On February 18, 2003, the Board of Directors granted replacement options to purchase 428,570 shares of Common Stock. Each of the replacement options has a ten-year term. The following table sets forth information concerning the options exchanged with respect to each of the Company’s executive officers.

Ten-Year Option Repricings

	Date		Number of securities underlying options/SARs repriced or amended		Market price of stock at time of repricing or amendment		Exercise price at time of repricing or amendment		New exercise price		Length of original option term remaining at date of repricing or amendment
Howard Root		N/A		-		N/A		N/A		N/A		N/A
Chief Executive Officer
Michael Nagel		2/18/03		10,000	$	0.84	$	3.00	$	0.84		65 months
Vice President of Sales		2/18/03		25,000		0.84		3.25		0.84		74 months
and Marketing and		2/18/03		15,000		0.84		6.00		0.84		82 months
Secretary		2/18/03		20,000		0.84		6.00		0.84		82 months
		2/18/03		20,000		0.84		7.31		0.84		95 months
James Quackenbush		2/18/03		27,500	$	0.84	$	3.25	$	0.84		72 months
Vice President of		2/18/03		2,500		0.84		3.25		0.84		74 months
Manufacturing		2/18/03		10,000		0.84		6.00		0.84		82 months
		2/18/03		10,000		0.84		7.31		0.84		95 months
Deborah Neymark		2/18/03		25,000	$	0.84	$	7.31	$	0.84		95 months
Vice President of
Regulatory Affairs,
Quality Systems &
Clinical Research
James Hennen		N/A		—		N/A		N/A		N/A		N/A
Chief Financial Officer

-16-

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

        The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 10, 2004 by each person, or group of affiliated persons, who is known by us to own beneficially more than 5% of our common stock, each of our directors and nominees for director, each of our executive officers named in the Summary Compensation Table above and all of our directors and executive officers as a group.

        Beneficial ownership is determined in accordance with the rules of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock under options held by that person that are currently exercisable or exercisable within 60 days of February 13, 2004 are considered outstanding. These shares, however, are not considered outstanding when computing the percentage ownership of each other person. The number of shares subject to options that each beneficial owner has the right to acquire within 60 days of February 13, 2003 are also listed separately under the column entitled “Number of Shares Underlying Options Beneficially Owned.”

        Except as indicated in the footnotes to this table, each shareholder named in the table has sole voting and investment power for the shares shown as beneficially owned by them. Percentage of ownership is based on 12,998,770 shares of common stock outstanding on February 13, 2004.

Name	Number of Shares Beneficially Owned	Number of Shares Underlying Options Beneficially Owned	Percent of Shares Outstanding
Entities affiliated with Stephens, Inc.(1)	2,172,954	40,000	16.7	%
James Jacoby, Jr.(1)	2,181,977	40,000	16.8
Howard Root	529,250	253,461	4.1
Richard Nigon(2)	35,500	30,000	*
Michael Kopp	30,000	20,000	*
Paul O'Connel	20,000	20,000	*
Gary Dorfman	20,000	20,000	*
John Erb	20,000	20,000	*
Michael Nagel(3)	207,808	140,600	1.6
James Quackenbush	58,672	50,500	*
Deborah Neymark	40,024	31,600	*
James Hennen	7,240	7,240	*
All directors and executive officers as a group
(10 persons)	3,150,471	633,401	24.2

_________________
*Less than 1%

-17-

⁽¹⁾ 1,610,036 of the shares are held by Stephens Vascular Preferred, LLC, 522,918 of the shares are held by Stephens Vascular Options, LLC and all of the options are held by Stephens Investment Partners III LLC. The address is 111 Center Street, Suite 2500, Little Rock, AR 72201. Mr. Jacoby is a Managing Director of Stephens Inc. and a member of Stephens Vascular Preferred, LLC and Stephens Vascular Options, LLC. Stephens Vascular Preferred, LLC, Stephens Vascular Options, LLC and Stephens Investment Partners III LLC are affiliates of Stephens Inc. and have contributed their shares of our common stock to a voting trust pursuant to which the trustee of the trust has sole voting power. The voting trust is required to vote such shares “for” or “against” proposals submitted to our shareholders in the same proportion as votes cast “for” and “against” those proposals by all other shareholders, excluding abstentions. The voting trust agreement also imposes substantial limitations on the sale or other disposition of the shares subject to the voting trust. The voting trust agreement expires in June 2010 or such earlier time as Stephens Inc. ceases to be a market maker of our common stock. The name and address of the trustee of the voting trust agreement are: James Sommers, 237 Cherokee Road, Charlotte, North Carolina 28207. Mr. Jacoby disclaims beneficial ownership of the shares subject to the voting trust agreement.

⁽²⁾
Includes 500 shares held by Mr. Nigon’s wife. Mr. Nigon disclaims beneficial ownership of the shares held in the name of his wife.

⁽³⁾
Includes an aggregate of 9,000 shares registered in the name of Mr. Nagel’s three minor children’s irrevocable trusts. Mr. Nagel disclaims beneficial ownership of the shares held in the name of his children.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

        Section 16(a) of the Securities Exchange Act of 1934 requires Vascular Solutions’ executive officers and directors and persons who beneficially own more than 10% of Vascular Solutions’ common stock to file initial reports of ownership and reports of changes in ownership with the Securities and Exchange Commission. Such executive officers, directors and greater than 10% beneficial owners are required by the regulations of the Commission to furnish Vascular Solutions with copies of all Section 16(a) reports they file.

        Based solely on a review of the copies of such reports furnished to Vascular Solutions and written representations from the executive officers and directors, Vascular Solutions believes that all Section 16(a) filing requirements applicable to its executive officers and directors and greater than 10% beneficial owners have been timely met.

-18-

SHAREHOLDER RETURN PERFORMANCE GRAPH

        The following graph shows a comparison of cumulative total returns for our common stock, the NASDAQ Stock Market Index (U.S.) and the NASDAQ Medical Industry Index (Medical Devices, Instruments and Supplies), assuming the investment of $100 in our common stock and each index on July 20, 2000 (the date our common stock began trading) and the reinvestment of dividends, if any.

-19-

PROPOSAL 2:
RATIFICATION OF APPOINTMENT OF AUDITOR

        Our Board of Directors has appointed Ernst & Young LLP as Vascular Solutions’ independent auditor for 2004. A proposal to ratify that appointment will be presented at the annual meeting of shareholders. Ernst & Young has served as our independent auditor since our inception. Representatives of Ernst & Young are expected to be present at the annual meeting of shareholders and will have an opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions from shareholders.

        OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS VASCULAR SOLUTIONS’ INDEPENDENT AUDITOR.

        The affirmative vote of a majority of the shares of Vascular Solutions common stock present and entitled to vote at the 2004 annual meeting of shareholders is necessary to ratify the appointment of Ernst & Young LLP. Proxies will be voted in favor of ratifying the appointment unless otherwise specified. If the appointment is not ratified by the shareholders, the Board of Directors is not obligated to appoint another auditor, but the Board of Directors will give consideration to an unfavorable vote.

ADDITONAL INFORMATION ABOUT OUR INDEPENDENT AUDITOR

Audit Fees

        Fees billed or are expected to be billed for audit services to Vascular Solutions by Ernst & Young LLP for the audit of our financial statements and for reviews of our financial statements included in our quarterly reports on Form 10-Q for the fiscal year ended December 31, 2003 and 2002 were $66,000 and $49,200, respectively.

Audit-Related Fees

        Fees billed or are expected to be billed to Vascular Solutions by Ernst & Young LLP for audit-related services provided during the fiscal year ended December 31, 2003 and 2002 were $1,500 and $0, respectively.

Tax Fees

        Fees billed or expected to be billed to Vascular Solutions by Ernst & Young LLP for tax compliance, tax advice and tax planning for the fiscal year ended December 31, 2003 and 2002 were $5,074 and $36,189, respectively.

All Other Fees

        No fees were billed or are expected to be billed to Vascular Solutions by Ernst & Young LLP for other services not included above during the fiscal year ended December 31, 2003 and 2002.

-20-

Pre-Approval Policies and Procedures

        The Audit Committee has adopted a policy that requires advance approval of all audit, audit-related, tax services, and other services performed by the independent auditor. The policy provides for pre-approval by the Audit Committee of specifically defined audit and non-audit services. Unless the specific service has been previously pre-approved with respect to that year, the Audit Committee must approve the permitted service before the independent auditor is engaged to perform it. The Audit Committee has delegated to the Chair of the Audit Committee authority to approve permitted service provided that the Chair reports any decisions to the Committee at its next scheduled meeting. All of the services performed by our independent auditor were pre-approved by the audit committee.

OTHER MATTERS

        As of this date, the Board of Directors does not know of any business to be brought before the annual meeting of shareholders other than as specified above. However, if any matters properly come before the meeting, it is the intention of the persons named in the enclosed proxy to vote such proxy in accordance with their judgment on such matters.

PROPOSALS FOR THE NEXT ANNUAL MEETING

        Any shareholder proposals to be considered for inclusion in Vascular Solutions’ proxy material for the 2005 annual meeting of shareholders must be received at Vascular Solutions’ principal executive office at 6464 Sycamore Court, Minneapolis, Minnesota 55369, no later than November 24, 2004. In connection with any matter to be proposed by a shareholder at the 2005 annual meeting, but not proposed for inclusion in Vascular Solutions’ proxy material, the proxy holders designated by Vascular Solutions for that meeting may exercise their discretionary voting authority with respect to that shareholder proposal if appropriate notice of that proposal is not received by Vascular Solutions at its principal executive office by February 7, 2005.

By order of the Board of Directors



Michael Nagel
Secretary

Dated: March 24, 2004

-21-

Exhibit A

Vascular Solutions, Inc.
Audit Committee Charter

Organization

The audit committee of the board of directors shall be comprised of at least three directors who are independent of management and the Company. Members of the audit committee shall be considered independent if they have no relationship to the Company that may interfere with the exercise of their independence from management and the Company. All audit committee members will be financially literate, and at least one member will have accounting or related financial management expertise.

Statement of Policy

The audit committee shall provide assistance to the directors in fulfilling their responsibility to the shareholders, potential shareholders, and investment community relating to corporate accounting, reporting practices of the company, and the quality and integrity of financial reports of the company. In so doing, it is the responsibility of the audit committee to maintain free and open communication between the directors, the independent auditors, the internal auditors, and the financial management of the company.

Responsibilities

The audit committee is responsible for the appointment, compensation and oversight of the work of any registered public accounting firm employed by the Company for the purpose of preparing or issuing an audit report or other related work. Any such accounting firm will report directly to the audit committee. The audit committee’s oversight role includes responsibility for resolving disagreements between management and the accounting firm regarding the Company’s financial reporting.

The Chairman of the audit committee will be designated and publicized as the person responsible for the receipt, retention and presentation to the full audit committee for action of complaints regarding accounting and internal accounting controls or auditing matters. Submissions by the Company’s employees of concerns regarding questionable accounting or auditing matters (which may be submitted on a confidential or anonymous basis) will be instructed to be communicated to the Chairman of the audit committee.

The audit committee has the specific authority to engage independent counsel and other advisors, as the committee deems appropriate, and may commit the financial resources the audit committee deems appropriate for such purposes.

In carrying out its responsibilities, the audit committee believes its policies and procedures should remain flexible, in order to best react to changing conditions and to ensure to the directors and shareholders that the corporate accounting and reporting practices of the company are in accordance with all requirements.

In carrying out these responsibilities, the audit committee will:

• Obtain the full board of directors’ approval of this Charter and review and reassess this Charter as conditions dictate.

• Review and recommend to the directors the independent auditors to be selected to audit the financial statements of the company and its divisions and subsidiaries.

• Have a clear understanding with the independent auditors that they are ultimately accountable to the board of directors and the audit committee, as the shareholders’ representatives, who have the ultimate authority in deciding to engage, evaluate, and if appropriate, terminate their services.

• Review and concur with management’s appointment, termination, or replacement of the director of internal audit.

• Meet with the independent auditors and financial management of the Company to review the scope of the proposed audit and timely quarterly reviews for the current year and the procedures to be utilized, the adequacy of the independent auditor’s compensation, and at the conclusion thereof review such audit or review, including any comments or recommendations of the independent auditors.

• Review with the independent auditors, the company’s internal auditor, and financial and accounting personnel, the adequacy and effectiveness of the accounting and financial controls of the company, and elicit any recommendations for the improvement of such internal controls or particular areas where new or more detailed controls or procedures are desirable. Particular emphasis should be given to the adequacy of internal controls to expose any payments, transactions, or procedures that might be deemed illegal or otherwise improper.

• Review reports received from regulators and other legal and regulatory matters that may have a material effect on the financial statements or related company compliance policies.

• Review the internal audit function of the company including the independence and authority of its reporting obligations, the proposed audit plans for the coming year, and the coordination of such plans with the independent auditors.

• Inquire of management, the internal auditor, and the independent auditors about significant risks or exposures and assess the steps management has taken to minimize such risks to the Company.

• Receive prior to each meeting, a summary of findings from completed internal audits and a progress report on the proposed internal audit plan, with explanations for any deviations from the original plan.

• Review the quarterly financial statements with financial management and the independent auditors prior to the filing of the Form 10-Q (or prior to the press release of results, if possible) to determine that the independent auditors do not take exception to the disclosure and content of the financial statements, and discuss any other matters required to be

A-2

communicated to the committee by the auditors. The chair of the committee may represent the entire committee for purposes of this review.

• Review the financial statements contained in the annual report to shareholders with management and the independent auditors to determine that the independent auditors are satisfied with the disclosure and content of the financial statements to be presented to the shareholders. Review with financial management and the independent auditors the results of their timely analysis of significant financial reporting issues and practices, including changes in, or adoptions of, accounting principles and disclosure practices, and discuss any other matters required to be communicated to the committee by the auditors. Also review with financial management and the independent auditors their judgments about the quality, not just acceptability, of accounting principles and the clarity of the financial disclosure practices used or proposed to be used, and particularly, the degree of aggressiveness or conservatism of the organization’s accounting principles and underlying estimates, and other significant decisions made in preparing the financial statements.

• Provide sufficient opportunity for the internal and independent auditors to meet with the members of the audit committee without members of management present. Among the items to be discussed in these meetings are the independent auditors’ evaluation of the company’s financial, accounting, and auditing personnel, and the cooperation that the independent auditors received during the course of audit.

• Report the results of the annual audit to the board of directors. If requested by the board, invite the independent auditors to attend the full board of directors meeting to assist in reporting the results of the annual audit or to answer other directors’ questions (alternatively, the other directors, particularly the other independent directors, may be invited to attend the audit committee meeting during which the results of the annual audit are reviewed).

• Review the nature and scope of other professional services provided to the company by the independent auditors and consider the relationship to the auditors’ independence.

• On an annual basis, obtain from the independent auditors a written communication delineating all their relationships and professional services as required by Independence Standards Board Standard No. 1, Independence Discussions with Audit Committees. In addition, review with the independent auditors the nature and scope of any disclosed relationships or professional services and take, or recommend that the board of directors take, appropriate action to ensure the continuing independence of the auditors.

• Review the report of the audit committee in the annual report to shareholders and the Annual Report on Form 10-K disclosing whether or not the committee had reviewed and discussed with management and the independent auditors, as well as discussed within the committee (without management or the independent auditors present), the financial statements and the quality of accounting principles and significant judgments affecting the financial statements. In addition, disclose the committee’s conclusion on the fairness of presentation of the financial statements in conformity with GAAP based on those discussions.

• Submit the minutes of all meetings of the audit committee to, or discuss the matters discussed at each committee meeting with, the board of directors.

A-3

• Investigate any matter brought to its attention within the scope of its duties, with the power to retain outside counsel for this purpose if, in its judgment, that is appropriate.

• Review the Company’s disclosure in the proxy statement for its annual meeting of shareholders that describes that the Committee has satisfied its responsibilities under this Charter for the prior year. In addition, include a copy of this Charter in the annual report to shareholders or the proxy statement at least triennially or the year after any significant amendment to the Charter.

A-4

VASCULAR SOLUTIONS, INC.

ANNUAL MEETING OF SHAREHOLDERS

Thursday, April 22, 2004
3:30 p.m.

Radisson Hotel & Conference Center
3131 Campus Drive
Plymouth, MN 55441

Vascular Solutions, Inc.
6464 Sycamore Court, Minneapolis, MN 55369 proxy

This proxy is solicited by the Board of Directors for use at the Annual Meeting on April 22, 2004.

The shares of stock you hold will be voted as you specify on the reverse side.

If no choice is specified, the proxy will be voted “FOR” Items 1 and 2.

By signing the proxy, you revoke all prior proxies and appoint Howard Root and Michael Nagel, and each of them, with full power of substitution, to vote your shares on the matters shown on the reverse side and any other matters which may come before the Annual Meeting and all adjournments.

See reverse for voting instructions.

The Board of Directors Recommends a Vote FOR Items 1 and 2.

1. Election of directors: 01 Paul O’Connell
02 James Jacoby, Jr.
03 Michael Kopp 04 Gary Dorfman
05 Richard Nigon 06 John Erb
07 Howard Root [  ] Vote FOR
all nominees
(except as marked) [  ] Vote WITHHELD
from all nominees

(Instructions: To withhold authority to vote for any indicated nominee,
write the number(s) of the nominee(s) in the box provided to the right.)

2.	Proposal to ratify the selection of Ernst and Young LLP as independent auditor of the Company for the year ending December 31, 2004.	[  ]	For	[  ]	Against	[  ]	Abstain
3.	To transact such other business as may properly come before the meeting or any adjournment thereof.

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, WILL BE VOTED
FOR EACH PROPOSAL.

Address Change? Mark Box [  ]
Indicate changes below:

Date
 

Signature(s) in Box
Please sign exactly as your name(s) appears on Proxy. If held in joint tenancy, all persons must sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the proxy.